Iron Chelator Transmetalative Approach to Inhibit Human Ribonucleotide Reductase
Posted by Adam Awdish on
Single Donor Human Red Blood Cells from Innovative Research were used in the following study:
Iron Chelator Transmetalative Approach to Inhibit Human Ribonucleotide Reductase
Kavita Gaur, Sofia C. Pérez Otero, Josué A. Benjamín-Rivera, Israel Rodríguez, Sergio A. Loza-Rosas, Alexandra M. Vázquez Salgado, Eman A. Akam, Liz Hernández-Matias, Rohit K. Sharma, Nahiara Alicea, Martin Kowaleff, Anthony V. Washington, Andrei V. Astashkin, Elisa Tomat, and Arthur D. Tinoco
JACS Au
May 25, 2021
Within the realm of cancer research and the search for new treatments, one area of interest is that of the relationship between Iron and cancer cells in the body. Iron is the most abundant metal in the body and is responsible for the transport of oxygen and electrons and is required for a wide range of cellular processes to take place such as DNA synthesis, cell cycle regulation, protein function, and more.
In this study, researchers looked at the possibility of treating/preventing cancer by inhibiting the bioavailability of Iron to cancer cells. They hypothesized that this would interrupt the cancer’s cellular cycle and trigger cell death.
Related products available from Innovative Research also include:
Single Donor Human Red Blood Cells Washed